8-K filing — Atrium Therapeutics, Inc. (RNA)
Filed: 2026-11-02 AccNo: 0001193125-26-442601 Size: 13 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Atrium Therapeutics to Present Nonclinical Data for ATR 1072 at AHA Scientific Sessions 2026
Atrium Therapeutics announced it will present new nonclinical data for its investigational therapy ATR 1072, intended for the treatment of PRKAG2 syndrome, at the upcoming American Heart Association Scientific Sessions.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Lowers Price Target for Atrium Therapeutics, Inc.
HC Wainwright & Co. has reduced its price target for Atrium Therapeutics, Inc. from $25.00 to $20.00 per share.
Atrium Therapeutics Doses First Patient in Corventis Clinical Trial
Atrium Therapeutics has initiated the Phase 1/2 Corventis clinical trial by dosing the first patient with ATR 1072 for the treatment of PRKAG2 syndrome.
This Constellation Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Buy ratings for CleanSpark, Constellation Energy and Atrium; Outperform for Kardigan; Neutral for Northwest Natural.
Roth Capital Initiates Coverage of Atrium Therapeutics, Inc. with Buy Rating
Roth Capital has initiated research coverage on Atrium Therapeutics, Inc. with a Buy rating.
Roth Capital Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $15